Functional Neuromodulation said yesterday that it has begun a pivotal clinical trial to assess deep brain stimulation (DBS) in patients with mild Alzheimer’s disease. The Minneapolis-based company said the study will evaluate the safety and efficacy of stimulating the fornix (DBS-f) — a major inflow and output pathway in the brain’s memory circuit. Research suggests […]
ReShape Lifesciences CEO Gladney to resign | Personnel Moves – January 29, 2019
ReShape Lifesciences (NSDQ:RSLS) said yesterday that its prez & CEO Dan Gladney will resign from his positions with the company, effective March 31. Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said. The company’s board of directors said they will immediately begin to look for a replacement, according to an […]
Alzheimer’s disease: FDA expands deep-brain stimulation trial
Toronto-based Functional Neuromodulation won FDA approval to expand the U.S. arm of its Alzheimer’s study from 20 to 30 patients who will receive the company’s deep brain stimulation implant.
The device maker is already halfway through initial enrollment for its ADvance trial, which was slated to enroll 20 U.S. and 20 Canadian patients with mild Alzheimer’s disease, provide them with DBS systems and compare the effects of the systems turned on versus systems turned off.
Report: Covidien to acquire superDimension for $350M | Wall Street Beat
Covidien (NYSE:COV) is set to close a $350 million buyout of Israeli lung diagnosis firm superDimension by the end of the week, according to Israeli business journal Calcalist.
Founded in Tel Aviv by Pinchas Gilboa, Minneapolis-based superDimension, which employs about 120 people worldwide, also has offices in Dusseldorf, Germany.
